937782-05-3
Chemical Structure
Difamilast
Synonym(s): OPA-15406
- CAS No.: 937782-05-3
- Formula:C23H24F2N2O5
- Molecular Weight:446.44
IUPAC Name: N-((2-(4-(difluoromethoxy)-3-isopropoxyphenyl)oxazol-4-yl)methyl)-2-ethoxybenzamide
InChIKey: VFBILHPIHUPBPZ-UHFFFAOYSA-N
SMILES: CC(C)OC(C=C(C1=NC(CNC(C(C=CC=C2)=C2OCC)=O)=CO1)C=C3)=C3OC(F)F
Biological Activity: Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Difamilast | 99.38% | Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Difamilast (Standard) | ≥98% | Difamilast (Standard) is the analytical standard of Difamilast. This product is intended for research and analytical applications. Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Hanifin JM, et, al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016 Aug;75(2):297-305. [Content Brief]
- [2]. Ahluwalia J, et, al. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook. Drugs. 2017 Sep;77(13):1389-1397. [Content Brief]
- [3]. Soeberdt M, et, al. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis. Eur J Pharmacol. 2020 Aug 15;881:173242. [Content Brief]
Keywords
